Pular para o conteúdo principal
Ranking Invest

RLAY - Relay Therapeutics, Inc.

Segmento: HealthcareRelay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Análise Ranking Invest

Valuation estimado
-$ 228.25 Mi
Valor de Mercado
$ 4.14 Bi
Desconto (AV)-1911.7%
IVR
-0.06A companhia vale -0,06 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.27O valuation alternativo equivale a -27% do valor de mercado da companhia.
MLL
-0.27O lucro líquido dos controladores em 16 trimestres equivale a -27% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 890.01 Mi

Dívida Líquida

-$ 121.19 Mi

L4T

-$ 286.04 Mi

MM4T

-6785.89%

Indicadores Básicos

ROE

-32.14%

Índices de Previsibilidade

Receita Líquida

G1.24

Lucro

A0.13

Margem

F2.37

Índices de Tendência

Receita Líquida

D2.87

Lucro

D1.56

Margem

B5.29

Índices de Endividamento

DIV/PAT

-0.14

DIV/L4T

0.42

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.